Panaxia and Neuraxpharm are the world's first companies to sell medical cannabis extracts for inhalation in Europe
Tel Aviv, November 3, 2021- Panaxia Labs Israel Ltd. (“Panaxia Israel,” TA: PNAX), a global pharma company that develops, manufactures and markets advanced medical cannabis products of pharmaceutical quality announced the first commercial export of its medical cannabis extracts for inhalation to Germany, where it will be marketed under the Naxiva-Panaxol brand, which Panaxia shares with its partner, Neuraxpharm, Europe's leading Pharma Company focused on the treatment of Central Nervous System (CNS) disorders.
The shipment left earlier this week to Germany, after the required tests are completed by the Israeli Health Authorities and the Israeli Customs.
The extracts for inhalation will be available in pharmacies
throughout Germany and will be dispensed against a branded prescription from a physician
for a wide variety of medical indications.
The first shipment follows the company’s announcement it had been
granted an import and sales permit for cannabis extracts for inhalation in
Germany, the first and only permit of its kind.
Following the approval, Panaxia and Neuraxpharm became the first
and only companies to import and market this type of advanced product in
Germany, and in Europe in general. This is in addition to its being the first
and only companies in Europe to have received a regulatory permit to distribute
medical cannabis sublingual tablets in France, as part of a French government
program by the Safety of Medicines and Health Products (ANSM). Additionally,
the company’s premium oils are marketed regularly in Germany, France, and
Cyprus.
The essences, which are manufactured by Panaxia and are EU-GMP
certified, are produced at strict pharmaceutical standards according to
know-how and clinical methods developed at the company. Neuraxpharm will market
the products in Germany to physicians certified to prescribe medical cannabis
products to patients to treat a wide variety of medical indications.
This week, first export of medical cannabis extracts for
inhalation left Israel to Germany, the largest and fastest growing medical
cannabis market in Europe
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance